Renal Cell Carcinoma

P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris

P1, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

The patient was managed by transurethral resection of bladder tumor (TURBT) followed by targeted therapy with sunitinib (37.5 mg)...ccRCC can metastasize to unusual sites, including the urinary bladder. Early recognition through comprehensive imaging and immunohistochemical evaluation is essential for timely diagnosis and management.

The patient and family moved locations before germline testing was done. Effective communication between care teams was essential to ensure continuity, with clear plans established for ongoing surveillance and any additional testing needed for both the child and family.

We identify a link between IL-6 expression and PIM1 expression and activity in human ccRCC tumors and cell lines. Our work provides evidence that targeting an IL-6/JAK/STAT/PIM1 axis may be a viable therapeutic strategy for patients with PIM1-high expressing ccRCC.

Interestingly, one antibody exhibited dual-reactive binding to VEGFA and PlGF-2, suggesting a novel therapeutic strategy to prevent PlGF-driven VEGF-resistance. Overall, these antibodies define new mechanisms to disrupt PlGF activity and support a role for NRP1 in cell proliferation.

P=N/A, N=70, Recruiting, Peking University First Hospital

P2, N=18, Active, not recruiting, Emory University | Trial completion date: Jan 2026 --> Dec 2026

P1, N=124, Recruiting, Pliant Therapeutics, Inc. | N=77 --> 124 | Trial completion date: Dec 2025 --> Jun 2030 | Trial primary completion date: Jun 2025 --> Jun 2030

P2/3, N=203, Recruiting, University College London | Not yet recruiting --> Recruiting

FLCN-mutated RCCs comprise a morphologically heterogeneous yet molecularly defined group. Conventional oncoytic morphology was associated with germline alterations while unclassified morphologies could be associated with somatic alterations and possibly germline mutations. FLCN mutations may also be incidental germline mutations in other RCC subtypes. Tumors with unclassified morphologies evoked morphological and immunohistochemical diagnostic consideration of other oncocytic and papillary RCCs and could be associated with adverse outcomes. Recognition may be aided by diffuse GPNMB expression, but definitive classification, especially in cases without conventional morphology, requires molecular testing. These findings broaden the spectrum of FLCN-driven tumors and support their distinction as a unique molecular entity.

Imaging performed after pathologic diagnosis revealed an unsuspected renal mass. This case highlights the importance of recognizing cytomorphologic features suggestive of metastatic renal cell carcinoma during intraoperative consultation and underscores the role of cytologic evaluation in guiding diagnostic workup and tissue management in patients presenting with cervical lymphadenopathy of unknown origin.